ELV forecasts a 29.8% year-over-year drop in Q2 EPS to $6.21 and a 1.6% revenue decline to $48.63B.
Elevance Health (ELV) will release its Q2 2026 earnings before the market opens on Wednesday, July 15. Analysts expect earnings per share of $6.21, reflecting a 29.8% decline from the same period last year, while revenue is projected at $48.63 billion, down 1.6% year-over-year.
The company has faced mixed performance over the past two years, with recent quarters showing pressure on profitability amid shifting healthcare dynamics. Consensus estimates suggest a challenging quarter, though prior results have occasionally outperformed expectations.
No immediate market reaction details are available ahead of the release.